HIT TO LEAD CHEMISTRY UNDER PERFORMANCE AREA 2 OF ID/IQ CONTRACT NO. HHSN271201800001I

根据 ID/IQ 合同编号 2 的绩效领域 HIT 领导化学

• 批准号: 10721063
• 负责人: MATT SURMAN
• 金额: $ 72.88万
• 依托单位: ALBANY MOLECULAR RESEARCH, INC.
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-28 至 2024-03-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10721063
• 关键词: Area; Award; Biological Assay; Chemistry; Computer Assisted; Contractor; Contracts; Excretory function; Helping to End Addiction Long-term; In Vitro; Lead; Logistics; Metabolism; Pain; Pain management; Parents; Performance; Prodrugs; Shipping; Speed; Structure-Activity Relationship; Toxicology; United States National Institutes of Health; University of Texas M D Anderson Cancer Center; absorption; clinical pain; computational chemistry; design; drug discovery; novel; novel therapeutics; small molecule; therapeutically effective

This study is part of the NIH’s Helping to End Addiction Long-term (HEAL) initiative to speed scientific solutions to understand the basis of pain and enhance clinical pain management. Task Order Number 75N95022F00007 tilted Grace (University of Texas MD Anderson Cancer Center) – MCSP – Hit to Lead Chemistry (Task Order)) is hereby awarded to Curia Global, Inc. (Contractor) under ID/IQ Contract HHSN271201800001I (Parent Contract). to develop structure activity relationship (SAR) analysis and design, synthesis, in vitro absorption, distribution, metabolism, excretion and toxicology (ADMET), computational chemistry/Computer Aided Drug Discovery (CADD), and compound logistics of storage and shipping to support the Contributor Grace (University of Texas MD Anderson Cancer Center) in developing a novel therapeutic effective in treating pain. This will be achieved by advancing the SAR/SPR of their small molecule prodrugs of starting small molecules utilizing their assays and in vitro ADMET to identify novel, prodrugs.

这项研究是美国国立卫生研究院帮助结束长期成瘾（HEAL）倡议的一部分，旨在加速科学解决方案，以了解疼痛的基础并加强临床疼痛管理。